Veradermics, a Connecticut biotech developing an oral formulation of the hair‑growth drug Rogaine, filed for an initial public offering to raise capital for clinical development, the company disclosed. The filing signals continued investor interest in dermatology and consumer‑facing biologics/small molecules. Veradermics will use proceeds to advance its oral candidate through additional studies and expand commercialization readiness.